E
EdiGene
Biotech & Life Sciences · Changping District, China · Founded 2015
Dedicated to the development of genome editing technology for human health MoreLess
EdiGene is a biotechnology company focused on translating cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer. The company leverages proprietary platforms to develop gene editing therapies for a range of diseases and conducts high throughput genome screening to dissect functional big data in biological contexts. EdiGene's proprietary High Throughput Genome Screening Platforms are built on advanced guide RNA design, extensive experience in cell library construction, cellular assays, and deep expertise in computational data analysis. EdiGene operates in the biotechnology and pharmaceutical markets, primarily serving clients in the healthcare sector, including research institutions and pharmaceutical companies. The business model revolves around developing and licensing gene editing therapies and providing high throughput genome screening services. Revenue is generated through partnerships, licensing agreements, and service fees for genome screening. Keywords: genome editing, gene therapy, biotechnology, cancer treatment, genetic diseases, drug discovery, high throughput screening, RNA design, cell library, computational analysis.
Company overview
EdiGene company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2015
- Headquarters
- Changping District, China
- Employees
- 46
- Open positions
- None listed
- Dealroom signal
- 34.9
Valuation & funding
EdiGene funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2021 | $62M | $335M | Alwin Capital · Loyal Valley Capital · IDG Capital · Lilly Asia Ventures | — |
| SERIES BOther financing | Oct 2020 | $67M | $268M | Sequoia · IDG Capital · Lilly Asia Ventures · Huagai Capital | — |
| EARLY VCOther financing | Sep 2019 | $12M | $46M | IDG Capital · Lilly Asia Ventures | — |
| EARLY VCOther financing | Feb 2019 | $10M | $73M | IDG Capital · Green Capital Partners · Lilly Asia Ventures | ↗ |
| EARLY VCOther financing | Aug 2018 | $15M | $58M | Undisclosed | — |
| SERIES AOther financing | Dec 2017 | FUJIFILM | — |
Growth signals
EdiGene website traffic
Latest recorded traffic for EdiGene is 2.5K monthly website visits, up 19% over the last three months. EdiGene's team grew 0% over the past year.
Hiring
Open positions at EdiGene
Current openings linked to this company in Dealroom.
Comparisons
EdiGene compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
EdiGene's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where EdiGene has talent and traffic
team presence
In the news
Latest news about EdiGene
Recent press, funding announcements, and product moves mentioning EdiGene — open to read from the original sources.
Market sentiment
What the market is saying about EdiGene
An AI-synthesized read of the highest-engagement posts about EdiGene on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EdiGene’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.